# Single Ascending Dose Study of TD-1439 in Healthy Subjects

> **NCT02903095** · PHASE1 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 66 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** TD-1439
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02903095
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09
- **Primary completion:** 2016-12
- **Final completion:** 2017-02
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2021-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02903095

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02903095, "Single Ascending Dose Study of TD-1439 in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02903095. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*